151 related articles for article (PubMed ID: 27997455)
1. Cervical Cancer Screening With Human Papillomavirus DNA and Cytology in Japan.
Sasaki Y; Iwanari O; Arakawa I; Moriya T; Mikami Y; Iihara K; Konno R
Int J Gynecol Cancer; 2017 Mar; 27(3):523-529. PubMed ID: 27997455
[TBL] [Abstract][Full Text] [Related]
2. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China.
Xu H; Lin A; Shao X; Shi W; Zhang Y; Yan W
Oncotarget; 2016 Dec; 7(50):83775-83783. PubMed ID: 27626178
[TBL] [Abstract][Full Text] [Related]
4. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
[TBL] [Abstract][Full Text] [Related]
6. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy.
Dijkstra MG; van Niekerk D; Rijkaart DC; van Kemenade FJ; Heideman DA; Snijders PJ; Meijer CJ; Berkhof J
Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):55-63. PubMed ID: 23733907
[TBL] [Abstract][Full Text] [Related]
7. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
[TBL] [Abstract][Full Text] [Related]
8. CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: Design, methods and baseline data of 18,471 women.
Morisada T; Teramoto K; Takano H; Sakamoto I; Nishio H; Iwata T; Hashi A; Katoh R; Okamoto A; Sasaki H; Nakatani E; Teramukai S; Aoki D
Cancer Epidemiol; 2017 Oct; 50(Pt A):60-67. PubMed ID: 28818742
[TBL] [Abstract][Full Text] [Related]
9. High-risk human papillomavirus detection in women with low-grade squamous intraepithelial lesions or higher-grade cytology using the Cervista HPV HR test.
Gold MA; Thomas MA; Huh WK; Sarto GE; Day SP
J Low Genit Tract Dis; 2013 Jan; 17(1):51-7. PubMed ID: 22885641
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology.
Rebolj M; Lynge E; Ejegod D; Preisler S; Rygaard C; Bonde J
Gynecol Oncol; 2014 Dec; 135(3):474-80. PubMed ID: 25449563
[TBL] [Abstract][Full Text] [Related]
11. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
[TBL] [Abstract][Full Text] [Related]
12. Management of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesions of the uterine cervix with human papilloma virus infection among young women aged less than 25 years.
Ryu KJ; Lee S; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
Diagn Cytopathol; 2016 Dec; 44(12):959-963. PubMed ID: 27714942
[TBL] [Abstract][Full Text] [Related]
13. Impact of the human papillomavirus status on the development of high-grade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at the baseline: A 9-year Swedish nested case-control follow-up study.
Fröberg M; Östensson E; Belkić K; Oštrbenk A; Poljak M; Mints M; Arbyn M; Andersson S
Cancer; 2019 Jan; 125(2):239-248. PubMed ID: 30536370
[TBL] [Abstract][Full Text] [Related]
14. Restriction of human papillomavirus DNA testing in primary cervical screening to women above age 30: systematic review.
Rebolj M; Njor SH; Lynge E
Eur J Cancer Prev; 2012 Jan; 21(1):73-81. PubMed ID: 21968690
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study.
Dong L; Wang MZ; Zhao XL; Feng RM; Hu SY; Zhang Q; Smith JS; Qiao YL; Zhao FH
Gynecol Oncol; 2018 Jan; 148(1):103-110. PubMed ID: 29169614
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.
Blatt AJ; Kennedy R; Luff RD; Austin RM; Rabin DS
Cancer Cytopathol; 2015 May; 123(5):282-8. PubMed ID: 25864682
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention.
Dovey de la Cour C; Guleria S; Nygård M; Trygvadóttir L; Sigurdsson K; Liaw KL; Hortlund M; Lagheden C; Hansen BT; Munk C; Dillner J; Kjaer SK
Cancer Med; 2019 Feb; 8(2):839-849. PubMed ID: 30632704
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis of studies evaluating the performance of point-of-care tests for human papillomavirus screening.
Kelly H; Mayaud P; Segondy M; Pant Pai N; Peeling RW
Sex Transm Infect; 2017 Dec; 93(S4):S36-S45. PubMed ID: 29223961
[TBL] [Abstract][Full Text] [Related]
19. Potential impact of combined high- and low-risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2.
Okadome M; Saito T; Tanaka H; Nogawa T; Furuta R; Watanabe K; Kita T; Yamamoto K; Mikami M; Takizawa K;
J Obstet Gynaecol Res; 2014 Feb; 40(2):561-9. PubMed ID: 24147758
[TBL] [Abstract][Full Text] [Related]
20. Changes in DNA Level of Oncogenic Human Papillomaviruses Other Than Types 16 and 18 in Relation to Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3.
Xi LF; Schiffman M; Hughes JP; Galloway DA; Koutsky LA; Kiviat NB
Cancer Epidemiol Biomarkers Prev; 2019 Aug; 28(8):1388-1394. PubMed ID: 31101617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
